135 related articles for article (PubMed ID: 20030421)
1. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.
Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Schacht A; Kadesjö B
Eur Child Adolesc Psychiatry; 2009 Dec; 18(12):725-35. PubMed ID: 19466476
[TBL] [Abstract][Full Text] [Related]
3. A review of atomoxetine effects in young people with developmental disabilities.
Aman MG; Smith T; Arnold LE; Corbett-Dick P; Tumuluru R; Hollway JA; Hyman SL; Mendoza-Burcham M; Pan X; Mruzek DW; Lecavalier L; Levato L; Silverman LB; Handen B
Res Dev Disabil; 2014 Jun; 35(6):1412-24. PubMed ID: 24732041
[TBL] [Abstract][Full Text] [Related]
4. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis and moderator analysis: can the field develop further?
Bloch MH
J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):135-7. PubMed ID: 24472248
[No Abstract] [Full Text] [Related]
6. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
Arnsten AF; Pliszka SR
Pharmacol Biochem Behav; 2011 Aug; 99(2):211-6. PubMed ID: 21295057
[TBL] [Abstract][Full Text] [Related]
7. Serotonin syndrome induced by overdose of atomoxetine alone in a patient with attention-deficit hyperactivity disorder: A case report.
Sato F; Suzuki A; Noto K; Shirata T; Kanno M; Kobayashi R; Otani K
PCN Rep; 2022 Sep; 1(3):e41. PubMed ID: 38868692
[TBL] [Abstract][Full Text] [Related]
8. Attention deficit hyperactivity disorder.
Thapar A; Cooper M
Lancet; 2016 Mar; 387(10024):1240-50. PubMed ID: 26386541
[TBL] [Abstract][Full Text] [Related]
9. Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD.
Snircova E; Marcincakova-Husarova V; Hrtanek I; Kulhan T; Ondrejka I; Nosalova G
Pediatr Int; 2016 Jun; 58(6):476-81. PubMed ID: 26579704
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic Biomarkers and Their Applications in Psychiatry.
Kam H; Jeong H
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33266292
[TBL] [Abstract][Full Text] [Related]
11. Effects of L-theanine-caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT.
Kahathuduwa CN; Wakefield S; West BD; Blume J; Dassanayake TL; Weerasinghe VS; Mastergeorge A
Sci Rep; 2020 Aug; 10(1):13072. PubMed ID: 32753637
[TBL] [Abstract][Full Text] [Related]
12. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
Mac Avin M; Teeling M; Bennett KE
BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
[TBL] [Abstract][Full Text] [Related]
13. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
Griffiths KR; Leikauf JE; Tsang TW; Clarke S; Hermens DF; Efron D; Williams LM; Kohn MR
J Psychiatr Res; 2018 Jul; 102():57-64. PubMed ID: 29674270
[TBL] [Abstract][Full Text] [Related]
14. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.
Katzman MA; Bilkey TS; Chokka PR; Fallu A; Klassen LJ
BMC Psychiatry; 2017 Aug; 17(1):302. PubMed ID: 28830387
[TBL] [Abstract][Full Text] [Related]
15. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse.
Sternat T; Katzman MA
Neuropsychiatr Dis Treat; 2016; 12():2149-64. PubMed ID: 27601909
[TBL] [Abstract][Full Text] [Related]
16. Dopamine and serotonin genetic risk scores predicting substance and nicotine use in attention deficit/hyperactivity disorder.
Groenman AP; Greven CU; van Donkelaar MM; Schellekens A; van Hulzen KJ; Rommelse N; Hartman CA; Hoekstra PJ; Luman M; Franke B; Faraone SV; Oosterlaan J; Buitelaar JK
Addict Biol; 2016 Jul; 21(4):915-23. PubMed ID: 25752199
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians.
Bushe CJ; Savill N
J Cent Nerv Syst Dis; 2011; 3():209-17. PubMed ID: 23861650
[TBL] [Abstract][Full Text] [Related]
18. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
Upadhyaya HP; Desaiah D; Schuh KJ; Bymaster FP; Kallman MJ; Clarke DO; Durell TM; Trzepacz PT; Calligaro DO; Nisenbaum ES; Emmerson PJ; Schuh LM; Bickel WK; Allen AJ
Psychopharmacology (Berl); 2013 Mar; 226(2):189-200. PubMed ID: 23397050
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
